- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Dividendenbekanntmachungen (02.01.2026) | 9.707 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIR PRODUCTS & CHEMICALS INC US0091581068 1,79 USD 1,5248 EUR ALICO INC US0162301040 0,05 USD 0,0425 EUR AMERICAN COASTAL INSURANCE... ► Artikel lesen | |
| 31.12.25 | Leerink Partners reiterates Outperform rating on XOMA stock at $45 target | 2 | Investing.com | ||
| 31.12.25 | Leerink Partners bestätigt Outperform-Rating für XOMA bei Kursziel von 45 US-Dollar | 1 | Investing.com Deutsch | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Takeda, XOMA ink new royalty agreement; amend existing deal | 3 | Seeking Alpha | ||
| 30.12.25 | XOMA und Takeda passen Lizenzvereinbarung an: Takeda erwirbt Mehrheit der Royalties für Mezagitamab zurück | 14 | Investing.com Deutsch | ||
| 30.12.25 | Takeda regains majority of mezagitamab royalty interest from XOMA | 4 | Investing.com | ||
| 30.12.25 | XOMA Royalty Corporation: XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab | 510 | GlobeNewswire (Europe) | - Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine... ► Artikel lesen | |
| 22.12.25 | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 4 | Seeking Alpha | ||
| 22.12.25 | XOMA Preferred Shares Series A declares $0.5391 dividend | 2 | Seeking Alpha | ||
| 22.12.25 | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Xoma acquires another struggling biotech, this time zeroing in on Generation Bio | 4 | FierceBiotech | ||
| 16.12.25 | 'Zombie' biotech buyer Xoma to acquire Generation Bio | 2 | BioPharma Dive | ||
| 16.12.25 | Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced | 1 | Investing.com | ||
| 15.12.25 | XOMA Royalty to acquire Generation Bio | 1 | Seeking Alpha | ||
| 15.12.25 | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | 247 | GlobeNewswire (Europe) | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| 12.12.25 | XOMA stock maintains Buy rating at Benchmark despite partner's trial setback | 1 | Investing.com | ||
| 11.12.25 | Why Is XOMA Royalty Stock Sinking Thursday? | 3 | Benzinga.com | ||
| 11.12.25 | XOMA stock price target lowered to $97 by H.C. Wainwright | 6 | Investing.com | ||
| 11.12.25 | Leerink Partners lowers XOMA stock price target on RZ358 trial failure | 2 | Investing.com | ||
| 11.12.25 | XOMA: Leerink Partners senkt Kursziel nach gescheiterter RZ358-Studie | 17 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
100 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,78 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | +4,28 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | 0,00 % | Piper Sandler stuft Erasca mit "Overweight" ein - Kursziel bei 5 US-Dollar | ||
| ALUMIS | 17,920 | 0,00 % | Should You Chase the Rally in Alumis Stock Today? | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,21 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | +4,41 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| TANGO THERAPEUTICS | 11,790 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 292,53 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| ADMA BIOLOGICS | 18,820 | +2,62 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,680 | +4,49 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,390 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
Das Unternehmen XOMA CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 21,400 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.